Tag
This article explores how acquired resistance to gemcitabine in pancreatic cancer leads to metabolic reprogramming that creates a vulnerability in the mevalonate pathway, offering a promising therapeutic target.
A landmark randomized trial demonstrates that atorvastatin reduces major cardiovascular events in adults aged 70 and older without established cardiovascular disease but does not extend disability-free survival, highlighting nuanced conside
Concise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for very
This review synthesizes evidence on statin therapy reducing hepatic decompensation and major adverse liver outcomes in primary biliary cholangitis, highlighting a recent robust target trial emulation study across diverse populations.
A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regul
A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially o
A large-scale study of over 700,000 young adults reveals a concerning decline in lipid follow-up and statin initiation between 2008 and 2018, highlighting a critical care gap in preventing premature cardiovascular disease during a key windo
This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly
Recent research uncovers that long-term statin use may prevent certain inflammation-driven cancers by blocking IL-33, heralding new possibilities in cancer prevention strategies.
Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.
This 5-year prospective cohort study reveals that high-dose statin therapy significantly slows abdominal aortic aneurysm growth and reduces the risks of repair, rupture, and death in men, suggesting benefits beyond traditional cardiovascula
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
